YOKNEAM, Israel, October 20, 2011 /PRNewswire/ --
eTwo
combines the unique Sublime™ and Sublative™ applications for
comprehensive facial rejuvenation
Syneron Medical Ltd. (NASDAQ: ELOS), http://www.syneron.com, the
global leader in medical aesthetic products and technology,
announced today the global launch of the new eTwo device, a
combination of advanced technologies for facial treatments, to be
showcased in the upcoming EADV 2011 - European Academy of
Dermatology and Venereology - Lisbon,
Portugal.
The eTwo is FDA cleared and CE marked for dermatological
procedures requiring ablation, resurfacing and wrinkle
treatment.
"We are extremely pleased to offer technological improvements in
a market that demands safe and effective solutions. eTwo's unique
combination of Sublime™ controlled heating and Sublative™
fractional skin treatment allows doctors and patients to see
dramatic results in skin texture and laxity both immediately and
over time as the rejuvenation process can continue for several
weeks after the procedure," said Louis
Scafuri, CEO of Syneron.
More specifically, Sublime™ uses the elos™ combination of safe
and effective levels of infrared light and bi-polar radio frequency
energies to remodel the deep dermal layer of the skin by
stimulating new collagen growth. At the same time, Syneron's
revolutionary Sublative™ fractionated bi-polar radio frequency
technology places heat energy in the upper layers of the dermis
allowing for a significant increase in collagen and elastin
production for a brighter and smoother complexion. This Sublative
breakthrough technology offers a high dermal impact with low
epidermal disruption. Together, these two applications are taking
skin rejuvenation treatments a step further.
The eTwo system supports the new Sublative iD tips,
intelligently designed tips to maximize treatment options and
results.
"I have consistently experienced impressive results when
treating patients with dyschromia and mild to moderate skin
laxity," says Brian Biesman, M.D,
F.A.C.S., Vanderbilt University Medical
Center Nashville, TN, who is part
of the on-going eTwo study.
According to Dr. Shimon Eckhouse,
Chairman of the Board of Syneron, "Our new eTwo device is in line
with our research and development based strategy that aims to reach
beyond existing technologies in order to provide our customers and
their patients with solutions that will better meet their needs and
expectations."
For more information about eTwo visit
http://www.syneron.com.
About Syneron Medical Ltd.
Syneron Medical Ltd. - is the leading global aesthetic device
company with a comprehensive product portfolio and a global
distribution footprint. The Company's technology enables physicians
to provide advanced solutions for a broad range of
medical-aesthetic applications including body contouring, hair
removal, wrinkle reduction, rejuvenation of the skin's appearance
through the treatment of superficial benign vascular and pigmented
lesions, and the treatment of acne, leg veins and cellulite. The
Company sells its products under two distinct brands, Syneron and
Candela. Founded in 2000, the corporate, R&D, and manufacturing
headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and
manufacturing operations in the US. The company markets and
services and supports its products in 86 countries. It has offices
in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan,
and Hong Kong and distributors
worldwide.
About eTwo™
eTwo™ is a comprehensive facial rejuvenation
device sold to professionals only. All information provided is
intended for informational purposes only. The information about
skin conditions provided herein does not constitute medical or
pharmaceutical advice and should not be relied upon as a substitute
for qualified medical consultation with health professionals.
Contacts:
Linda.Pavy@bm.com - Burson-Marsteller Agency
+ 33-1 41-86-76-26
Syneron PR - pr@syneron.com
Asaf Alperovitz - Syneron Chief
Financial Officer
+ 972-73-244-2283